[go: up one dir, main page]

WO2004108664A3 - Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung - Google Patents

Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung Download PDF

Info

Publication number
WO2004108664A3
WO2004108664A3 PCT/EP2004/005965 EP2004005965W WO2004108664A3 WO 2004108664 A3 WO2004108664 A3 WO 2004108664A3 EP 2004005965 W EP2004005965 W EP 2004005965W WO 2004108664 A3 WO2004108664 A3 WO 2004108664A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
bicyclic heterocycles
preparing
same
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2004/005965
Other languages
English (en)
French (fr)
Other versions
WO2004108664A2 (de
Inventor
Frank Himmelsbach
Rainer Soyka
Birgit Jung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim International GmbH
Priority to EP04739543A priority Critical patent/EP1641767A2/de
Priority to CA002526995A priority patent/CA2526995A1/en
Priority to JP2006508256A priority patent/JP2006527176A/ja
Publication of WO2004108664A2 publication Critical patent/WO2004108664A2/de
Publication of WO2004108664A3 publication Critical patent/WO2004108664A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)

Abstract

Die vorliegende Erfindung betrifft bicyclische Heterocyclen der allgemeinen Formel (I), in der Ra, Rb, Rc, Rd, X und n wie im Anspruch 1 definiert sind, deren Tautomere, deren Stereoisomere, deren Gemische und deren Salze, insbesondere deren physiologisch verträgliche Salze mit anorganischen oder organischen Säuren, welche wertvolle pharmakologische Eigenschaften aufweisen, insbesondere eine Hemmwirkung auf die durch Tyrosinkinasen vermittelte Signaltransduktion, deren Verwendung zur Behandlung von Krankheiten, insbesondere von Tumorerkrankungen sowie der benignen Prostatahyperplasie (BPH), von Erkrankungen der Lunge und der Atemwege und deren Herstellung.
PCT/EP2004/005965 2003-06-06 2004-06-02 Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung Ceased WO2004108664A2 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP04739543A EP1641767A2 (de) 2003-06-06 2004-06-02 Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
CA002526995A CA2526995A1 (en) 2003-06-06 2004-06-02 Bicyclic heterocycles, drugs containing said compounds, the use thereof and method for preparing the same
JP2006508256A JP2006527176A (ja) 2003-06-06 2004-06-02 二環式複素環化合物、該化合物を含む医薬品、その使用と製造方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10326186.9 2003-06-06
DE10326186A DE10326186A1 (de) 2003-06-06 2003-06-06 Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung

Publications (2)

Publication Number Publication Date
WO2004108664A2 WO2004108664A2 (de) 2004-12-16
WO2004108664A3 true WO2004108664A3 (de) 2005-05-26

Family

ID=33482765

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/005965 Ceased WO2004108664A2 (de) 2003-06-06 2004-06-02 Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung

Country Status (11)

Country Link
US (3) US7196091B2 (de)
EP (1) EP1641767A2 (de)
JP (1) JP2006527176A (de)
AR (1) AR044604A1 (de)
CA (1) CA2526995A1 (de)
CL (1) CL2004001409A1 (de)
DE (1) DE10326186A1 (de)
PE (1) PE20050227A1 (de)
TW (1) TW200510341A (de)
UY (1) UY28347A1 (de)
WO (1) WO2004108664A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078735A1 (de) 1999-06-21 2000-12-28 Boehringer Ingelheim Pharma Kg Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
DE10204462A1 (de) * 2002-02-05 2003-08-07 Boehringer Ingelheim Pharma Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
US6924285B2 (en) * 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
DE10221018A1 (de) * 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
US7456189B2 (en) * 2003-09-30 2008-11-25 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
US20050096332A1 (en) * 2003-10-30 2005-05-05 Boehringer Ingelheim International Gmbh Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
CA2627590A1 (en) * 2005-07-04 2007-01-11 Boehringer Ingelheim International Gmbh Method for the production of quinazolinone derivatives
JP5688877B2 (ja) 2005-11-11 2015-03-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌疾患の治療用キナゾリン誘導体
WO2007101782A1 (de) * 2006-03-09 2007-09-13 Boehringer Ingelheim International Gmbh Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
SI2068880T1 (sl) 2006-09-18 2012-08-31 Boehringer Ingelheim Int Postopek za zdravljenje raka, ki vsebuje mutacije EGFR
EP1921070A1 (de) * 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
EA200901041A1 (ru) * 2007-02-06 2010-02-26 Бёрингер Ингельхайм Интернациональ Гмбх Бициклические гетероциклы, содержащие эти соединения лекарственные средства, их применение и способ их получения
RS52573B (sr) 2008-02-07 2013-04-30 Boehringer Ingelheim International Gmbh Spirociklični heterocikli, lekovi koji sadrže navedeno jedinjenje, njihova primena i postupak za njihovu proizvodnju
CA2733153C (en) * 2008-08-08 2016-11-08 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
JP5963672B2 (ja) 2009-07-06 2016-08-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｉｂｗ２９９２、その塩及びこの活性成分を含む固体医薬製剤の乾燥方法
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
CN105418517B (zh) * 2015-12-03 2017-03-22 中国人民解放军南京军区南京总医院 一种新型喹唑啉衍生物lu1509及其制备方法和应用
CN105399689B (zh) * 2015-12-03 2017-03-01 中国人民解放军南京军区南京总医院 一种新型喹唑啉衍生物lu1503及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996033980A1 (en) * 1995-04-27 1996-10-31 Zeneca Limited Quinazoline derivatives
WO2000055141A1 (en) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, and processes for preparing them
WO2002018351A1 (de) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und vefahren zu ihrer herstellung

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996033977A1 (en) * 1995-04-27 1996-10-31 Zeneca Limited Quinazoline derivatives
CN1240688C (zh) * 2000-04-07 2006-02-08 阿斯特拉曾尼卡有限公司 喹唑啉化合物
US6656946B2 (en) 2000-08-26 2003-12-02 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996033980A1 (en) * 1995-04-27 1996-10-31 Zeneca Limited Quinazoline derivatives
WO2000055141A1 (en) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, and processes for preparing them
WO2002018351A1 (de) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und vefahren zu ihrer herstellung

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BARKER, A. J. ET AL: "Studies leading to the identification of ZD1839 (iressa): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS , 11(14), 1911-1914 CODEN: BMCLE8; ISSN: 0960-894X, 2001, XP002303977 *
GORE, JEFF ET AL.: "The Structure of a Human Metabolite of Pholcodine", AUST. J. CHEM., vol. 49, no. 11, 1996, pages 1235 - 1242, XP009044167 *
KASHIMA, CHOJI; HARADA, KAZUO: "Synthesis and Reaction of Optically Active Morpholinones", J. CHEM. SOC. PERKIN TRANS. 1, 1988, pages 1521 - 1526, XP009044168 *

Also Published As

Publication number Publication date
PE20050227A1 (es) 2005-05-18
CA2526995A1 (en) 2004-12-16
US20060264450A1 (en) 2006-11-23
JP2006527176A (ja) 2006-11-30
EP1641767A2 (de) 2006-04-05
UY28347A1 (es) 2005-01-31
CL2004001409A1 (es) 2005-05-06
WO2004108664A2 (de) 2004-12-16
US7196091B2 (en) 2007-03-27
AR044604A1 (es) 2005-09-21
US20050014772A1 (en) 2005-01-20
TW200510341A (en) 2005-03-16
DE10326186A1 (de) 2004-12-23
US20100267718A1 (en) 2010-10-21

Similar Documents

Publication Publication Date Title
WO2004108664A3 (de) Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
CA2417652A1 (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
CA2417897A1 (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
CA2368059A1 (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
CA2403152A1 (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
AU2001295482A1 (en) Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof
MY127771A (en) Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
CA2375259A1 (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
MY136086A (en) Quinazoline derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
MXPA05008780A (es) Heterociclos biciclicos, medicamentos que contienen estos compuestos, su utilizacion y preocedimientos para su preparacion.
CA2417050A1 (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
CA2361174A1 (en) 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases
CA2432872A1 (en) Pyrazole compounds useful as protein kinase inhibitors
WO2002057261A3 (en) Diaminothiazoles and their use as inhibitors of cyclin-dependent kinase
YU30902A (sh) Novi ciklopropani kao cgrp antagonisti, lekovi koji sadrže navedena jedinjenja i postupak za njihovu proizvodnju
EA201001241A1 (ru) Спирогетероциклы, содержащие эти соединения лекарственные средства, их применение и способ их получения
MX2009007610A (es) Heterociclicos biciclicos, medicamentos que contienen estos compuestos, su utilizacion y procedimientos para su preparacion.
WO2000055162A3 (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
DE69907419D1 (en) Antitumorwirkstoffe
WO2001010860A3 (en) Quinazolinone and azaquinazolinone derivatives
WO2003080617A8 (en) Pyrazolopyrimidine derivatives
YU19302A (sh) 4-benzilaminohinolin konjugovan žučnom kiselinom i njegovi heteroanalozi, postupak za njihovu proizvodnju, lekovi koji sadrže ta jedinjenja i njihova primena
WO2004108094A3 (en) Sulfonamide-substituted chalcone derivatives and their use to treat diseases
MY140484A (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
CY1116921T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις, φαρμακα που περιεχουν τις ενωσεις αυτες, χρηση αυτων και μεθοδος για την παραγωγη τους

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004739543

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2526995

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006508256

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2004739543

Country of ref document: EP